STOCK TITAN

Tax withholding moves 37,898 Elanco (ELAN) CEO shares at $24.88

Filing Impact
(Very High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Elanco Animal Health Inc President, CEO and Director Jeffrey N. Simmons reported a tax-withholding disposition of 37,898 shares of common stock on March 3, 2026. The disposition, coded as a payment of tax liability, was priced at $24.88 per share.

After this transaction, Simmons directly held 2,051,898 shares of Elanco common stock. A separate line shows an indirect holding of 167,000 shares held by a revocable trust, reported as indirect beneficial ownership.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Simmons Jeffrey N

(Last) (First) (Middle)
C/O ELANCO ANIMAL HEALTH INCORPORATED
450 ELANCO CIRCLE

(Street)
INDIANAPOLIS IN 46221

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Elanco Animal Health Inc [ ELAN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
PRESIDENT, CEO AND DIRECTOR
3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/03/2026 F 37,898 D $24.88 2,051,898 D
Common Stock 167,000 I By Revocable Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Amy C. Seidel, as Attorney-in-Fact for Jeffrey N. Simmons 03/05/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Elanco (ELAN) CEO Jeffrey N. Simmons report?

Jeffrey N. Simmons reported a tax-withholding disposition of Elanco common stock. On March 3, 2026, he disposed of 37,898 shares at $24.88 per share to satisfy tax obligations associated with equity compensation.

How many Elanco (ELAN) shares did Jeffrey N. Simmons dispose of for taxes?

Jeffrey N. Simmons disposed of 37,898 shares of Elanco common stock for tax withholding. The transaction was coded as payment of tax liability, with a reported price of $24.88 per share on March 3, 2026.

How many Elanco (ELAN) shares does Jeffrey N. Simmons hold after the reported transaction?

After the tax-withholding disposition, Jeffrey N. Simmons directly held 2,051,898 shares of Elanco common stock. The filing also reports an additional 167,000 shares held indirectly through a revocable trust as of the same date.

What does the tax-withholding code F mean in the Elanco (ELAN) Form 4 filing?

Code F in the Form 4 indicates a payment of exercise price or tax liability by delivering securities. In this case, Elanco CEO Jeffrey N. Simmons used 37,898 shares to satisfy tax obligations rather than selling them in an open-market trade.

What indirect ownership in Elanco (ELAN) does Jeffrey N. Simmons report?

Jeffrey N. Simmons reports indirect ownership of 167,000 Elanco common shares held by a revocable trust. This line is classified as indirect beneficial ownership and reflects holdings separate from his directly owned 2,051,898 shares after the reported transaction.
Elanco Animal Health

NYSE:ELAN

ELAN Rankings

ELAN Latest News

ELAN Latest SEC Filings

ELAN Stock Data

12.15B
490.37M
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
INDIANAPOLIS